Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:00096155 | Liver | Cirrhotic | response to virus | 126/4634 | 367/18723 | 2.10e-05 | 2.77e-04 | 126 |
GO:0051607 | Liver | Cirrhotic | defense response to virus | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
GO:0140546 | Liver | Cirrhotic | defense response to symbiont | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:0002224 | Liver | HCC | toll-like receptor signaling pathway | 67/7958 | 121/18723 | 2.87e-03 | 1.34e-02 | 67 |
GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
GO:00022214 | Oral cavity | OSCC | pattern recognition receptor signaling pathway | 95/7305 | 172/18723 | 1.11e-05 | 1.15e-04 | 95 |
GO:00022243 | Oral cavity | OSCC | toll-like receptor signaling pathway | 63/7305 | 121/18723 | 2.36e-03 | 1.04e-02 | 63 |
GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
GO:000961520 | Thyroid | PTC | response to virus | 162/5968 | 367/18723 | 4.52e-07 | 7.41e-06 | 162 |
GO:00022215 | Thyroid | PTC | pattern recognition receptor signaling pathway | 77/5968 | 172/18723 | 2.56e-04 | 1.84e-03 | 77 |
GO:00516077 | Thyroid | PTC | defense response to virus | 108/5968 | 265/18723 | 1.34e-03 | 7.55e-03 | 108 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UNC93B1 | SNV | Missense_Mutation | novel | c.703N>A | p.Ala235Thr | p.A235T | Q9H1C4 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UNC93B1 | SNV | Missense_Mutation | rs779331638 | c.620N>A | p.Arg207Gln | p.R207Q | Q9H1C4 | protein_coding | tolerated(0.17) | benign(0.389) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
UNC93B1 | SNV | Missense_Mutation | | c.1057N>A | p.Glu353Lys | p.E353K | Q9H1C4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UNC93B1 | SNV | Missense_Mutation | | c.941N>T | p.Thr314Met | p.T314M | Q9H1C4 | protein_coding | tolerated(0.06) | probably_damaging(0.988) | TCGA-D1-A16F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
UNC93B1 | SNV | Missense_Mutation | | c.1057N>A | p.Glu353Lys | p.E353K | Q9H1C4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
UNC93B1 | SNV | Missense_Mutation | novel | c.364G>A | p.Ala122Thr | p.A122T | Q9H1C4 | protein_coding | deleterious(0.01) | benign(0.207) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
UNC93B1 | SNV | Missense_Mutation | novel | c.1666C>T | p.His556Tyr | p.H556Y | Q9H1C4 | protein_coding | tolerated_low_confidence(0.09) | benign(0) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
UNC93B1 | insertion | Frame_Shift_Ins | novel | c.1271_1272insA | p.Val425CysfsTer72 | p.V425Cfs*72 | Q9H1C4 | protein_coding | | | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
UNC93B1 | SNV | Missense_Mutation | novel | c.283C>T | p.Arg95Cys | p.R95C | Q9H1C4 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-NI-A8LF-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
UNC93B1 | SNV | Missense_Mutation | | c.333N>T | p.Met111Ile | p.M111I | Q9H1C4 | protein_coding | tolerated(0.29) | benign(0.023) | TCGA-05-4425-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |